Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children

JAMA Pediatrics

Volumn 167, Issue 12, 2013, Pages 1111-1117

  Rowhani Rahbar, Ali ^a,h   Fireman, Bruce ^a   Lewis, Edwin ^a   Nordin, James ^b   Naleway, Allison ^c   Jacobsen, Steven J ^a   Jackson, Lisa A ^d   Tse, Alison ^e   Belongia, Edward A ^f   Hambidge, Simon J ^a   Weintraub, Eric ^g   Baxter, Roger ^a   Klein, Nicola P ^a  

^a KAISER PERMANENTE   (United States)

^b Health Partners Institute for Education and Research   (United States)

^c CENTER FOR HEALTH RESEARCH   (United States)

^d GROUP HEALTH RESEARCH INSTITUTE   (United States)

^e HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

^f MARSHFIELD CLINIC   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS RUBELLA VACCINE;

AGE; ARTICLE; ATTRIBUTABLE RISK; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG FEVER; FEBRILE CONVULSION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; VACCINATION REACTION;

AGE FACTORS; CHICKENPOX VACCINE; CHILD; COHORT STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FEVER; HUMANS; IMMUNIZATION; INCIDENCE; INFANT; MALE; MEASLES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEIZURES; SEIZURES, FEBRILE;

EID: 84890015233     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2013.2745     Document Type: Article

References (28)

1. Atkinson W, Wolfe C, Hamborsky J, eds. Epidemiology and Prevention of Vaccine- Preventable Diseases. 12th ed.Washington, DC: The Public Health Foundation; 2012.
2. Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-3):1-12.
3. US vaccination coverage reported via NIS. Centers for Disease Control and Prevention website. http://www.cdc.gov/vaccines/stats-surv /nis/default. htm#nis. Accessed September 20, 2013.
4. Klein NP, Fireman B, Yih WK, et al; Vaccine Safety Datalink. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1):e1-e8.
5. BarlowWE, Davis RL, Glasser JW, et al; Centers for Disease Control and Prevention Vaccine Safety DatalinkWorking Group. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med. 2001;345(9):656-661.
6. Griffin MR, RayWA, Mortimer EA, Fenichel GM, SchaffnerW. Risk of seizures after measles-mumps-rubella immunization. Pediatrics. 1991;88(5):881-885.
7. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first doseMMRV vaccination in amanaged care setting. Vaccine. 2009;27(34):4656-4661.
8. VestergaardM, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA. 2004;292(3):351-357.
9. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995;345(8949):567-569.
10. Strebel PM, PapaniaMJ, Dayan GH, Halsey NA. Measles vaccine. In: Plotkin SA, OrensteinWA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: Saunders Elsevier; 2008.
11. Verburgh ME, BruijnzeelsMA, van derWouden JC, et al. Incidence of febrile seizures in the Netherlands. Neuroepidemiology. 1992;11(4-6):169-172.
12. VestergaardM, Christensen J. Register-based studies on febrile seizures in Denmark. Brain Dev. 2009;31(5):372-377.
13. Van der Berg BJ, Yerushalmy J. Studies on convulsive disorders in young children, I: incidence of febrile and nonfebrile convulsions by age and other factors. Pediatr Res. 1969;3(4):298-304.
14. HuangWT, Gargiullo PM, Broder KR, et al; Vaccine Safety Datalink Team. Lack of association between acellular pertussis vaccine and seizures in early childhood. Pediatrics. 2010;126(2):263-269.
15. Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM; VSD Rapid Cycle Analysis InfluenzaWorking Group. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine. 2012;30(11):2024-2031.
16. Chen RT, DeStefano F, Davis RL, et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ. 2000;78(2):186-194.]
17. DeStefano F; Vaccine Safety Datalink Research Group. The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf. 2001;10(5):403-406.
18. Baggs J, Gee J, Lewis E, et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics. 2011;127(suppl 1):S45-S53.
19. Yih WK, Kulldorff M, Fireman BH, et al. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics. 2011;127(suppl 1):S54-S64.
20. Lieu TA, Kulldorff M, Davis RL, et al; Vaccine Safety Datalink Rapid Cycle Analysis Team. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care.2007;45(10)(suppl 2):S89-S95.
21. Klein NP, Lewis E, Baxter R, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012;129(5):809-814.
22. Gillet Y, Steri GC, Behre U, et al. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine. 2009;27(3):446-453.
23. Blatter MM, Klein NP, Shepard JS, et al. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age. Pediatr Infect Dis J. 2012;31(8):e133-e140.
24. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine: a double-blind placebo-controlled trial in twins. Lancet. 1986;1(8487):939-942.
25. Glanz JM, McClure DL, Xu S, et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiol. 2006;59(8):808-818.
26. Rowhani-Rahbar A, Klein NP, Dekker CL, et al; Risk IntervalWorking Group of the Clinical Immunization Safety Assessment Network. Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine. 2012;31(1):271-277.
27. OrensteinWA, Markowitz L, Preblud SR, Hinman AR, Tomasi A, Bart KJ. Appropriate age for measles vaccination in the United States. Dev Biol Stand. 1986;65:13-21.
28. Kuter BJ, Brown ML, Hartzel J, et al; Study Group for ProQuad. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccin. 2006;2(5):205-214.